[
  {
    "ts": "2026-02-11T01:31:00+00:00",
    "headline": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
    "summary": "Could these two companies be biotech giants in the making?",
    "url": "https://www.fool.com/investing/2026/02/10/missed-out-on-eli-lilly-2-healthcare-stocks-with-b/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "443a253e-838d-3f59-b49f-eb855f1a4d69",
      "content": {
        "id": "443a253e-838d-3f59-b49f-eb855f1a4d69",
        "contentType": "STORY",
        "title": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
        "description": "",
        "summary": "Could these two companies be biotech giants in the making?",
        "pubDate": "2026-02-11T01:31:00Z",
        "displayTime": "2026-02-11T01:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/311dc6a28d643b0bf2671d7d68071583",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "Person injecting a GLP-1 drug into their upper arm.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IuM39n9wWtp1xvZdb6iZ8Q--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/311dc6a28d643b0bf2671d7d68071583.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zEIN08ZuRqyC97nHHAd5Dg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/311dc6a28d643b0bf2671d7d68071583.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/10/missed-out-on-eli-lilly-2-healthcare-stocks-with-b/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/missed-eli-lilly-2-healthcare-013100642.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "INTC"
            },
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "ABVX"
            },
            {
              "symbol": "NVDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T04:34:49+00:00",
    "headline": "Eli Lilly Broadens Genetic Medicine Portfolio While Shares Screen As Undervalued",
    "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics to expand its genetic medicine and in vivo cell therapy efforts, focused on engineered circular RNA and autoimmune disease targets. The company also entered a multi billion dollar collaboration with Innovent Biologics to co develop new oncology and immunology drugs for global markets. Both transactions are aimed at broadening Lilly's pipeline beyond its existing focus areas of obesity and diabetes. For you as an investor, these deals...",
    "url": "https://finance.yahoo.com/news/eli-lilly-broadens-genetic-medicine-043449819.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "029b90f7-5bbc-3b06-94ae-c2b07214953f",
      "content": {
        "id": "029b90f7-5bbc-3b06-94ae-c2b07214953f",
        "contentType": "STORY",
        "title": "Eli Lilly Broadens Genetic Medicine Portfolio While Shares Screen As Undervalued",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics to expand its genetic medicine and in vivo cell therapy efforts, focused on engineered circular RNA and autoimmune disease targets. The company also entered a multi billion dollar collaboration with Innovent Biologics to co develop new oncology and immunology drugs for global markets. Both transactions are aimed at broadening Lilly's pipeline beyond its existing focus areas of obesity and diabetes. For you as an investor, these deals...",
        "pubDate": "2026-02-11T04:34:49Z",
        "displayTime": "2026-02-11T04:34:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-broadens-genetic-medicine-043449819.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-broadens-genetic-medicine-043449819.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "IVBIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T06:35:00+00:00",
    "headline": "Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore",
    "summary": "This stock has been known to soar after good news.",
    "url": "https://www.fool.com/investing/2026/02/11/viking-therapeutics-the-undertheradar-glp1-contend/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "0099994a-1982-3bb2-8b6f-a6988cdcbe06",
      "content": {
        "id": "0099994a-1982-3bb2-8b6f-a6988cdcbe06",
        "contentType": "STORY",
        "title": "Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore",
        "description": "",
        "summary": "This stock has been known to soar after good news.",
        "pubDate": "2026-02-11T06:35:00Z",
        "displayTime": "2026-02-11T06:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/48a1f3ca98aa348f63fddfd1e458fb76",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A group of investors cheers in an office.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Jvp4kwbYQI1HSof4LKBy9g--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/48a1f3ca98aa348f63fddfd1e458fb76.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VQUeqlC8f4I4304.THwjQA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/48a1f3ca98aa348f63fddfd1e458fb76.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/11/viking-therapeutics-the-undertheradar-glp1-contend/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viking-therapeutics-under-radar-glp-063500953.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T05:41:38+00:00",
    "headline": "The Top 5 Analyst Questions From Eli Lilly’s Q4 Earnings Call",
    "summary": "Eli Lilly's fourth quarter performance was defined by accelerating demand for its obesity and diabetes medicines, as well as rapid uptake in international markets. Management highlighted the strong contribution from Mounjaro and Zepbound, noting that volume growth in these products was the primary driver of revenue gains. CEO David Ricks underscored the impact of new product launches and expanded manufacturing capacity, stating, “We delivered robust revenue growth, advanced our pipeline, expande",
    "url": "https://finance.yahoo.com/news/top-5-analyst-questions-eli-054138431.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "88005a70-ad81-39f4-b82c-137a68eace59",
      "content": {
        "id": "88005a70-ad81-39f4-b82c-137a68eace59",
        "contentType": "STORY",
        "title": "The Top 5 Analyst Questions From Eli Lilly’s Q4 Earnings Call",
        "description": "",
        "summary": "Eli Lilly's fourth quarter performance was defined by accelerating demand for its obesity and diabetes medicines, as well as rapid uptake in international markets. Management highlighted the strong contribution from Mounjaro and Zepbound, noting that volume growth in these products was the primary driver of revenue gains. CEO David Ricks underscored the impact of new product launches and expanded manufacturing capacity, stating, “We delivered robust revenue growth, advanced our pipeline, expande",
        "pubDate": "2026-02-11T05:41:38Z",
        "displayTime": "2026-02-11T05:41:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "LLY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y7jUkGcVljBpqcrgSnimZQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fw6rZdJZ6CRFkLxhDmPhew--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-5-analyst-questions-eli-054138431.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-5-analyst-questions-eli-054138431.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T15:35:00+00:00",
    "headline": "Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.",
    "summary": "Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.",
    "url": "https://www.fool.com/investing/2026/02/11/healthcare-stock-sink-buy-dip-pfe-lly-nvo/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "f672f5cd-120a-3c48-b229-0fb9c3715316",
      "content": {
        "id": "f672f5cd-120a-3c48-b229-0fb9c3715316",
        "contentType": "STORY",
        "title": "Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.",
        "description": "",
        "summary": "Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.",
        "pubDate": "2026-02-11T15:35:00Z",
        "displayTime": "2026-02-11T15:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/44f260e24493a6c08c874d6a367d54b7",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "Weight loss drugs in a box.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HOakPIrPMZzDxJsu3ZTwFA--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/44f260e24493a6c08c874d6a367d54b7.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xNt10sy25xjDsXix7qMQcw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/44f260e24493a6c08c874d6a367d54b7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/11/healthcare-stock-sink-buy-dip-pfe-lly-nvo/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/healthcare-stocks-sinking-2-buy-153500199.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]